Just over a month after the U.S. Food and Drug Administration revoked its approval of Avastin for patients with breast cancer, a new report has revealed that the drug may be beneficial for sufferers of ovarian cancer, reports MyHealthNewsDaily.

Published in the latest edition of the New England Journal of Medicine, a study of women with advanced ovarian cancer showed that Avastin reportedly prolonged the timelines for progression by an average of four months. These women took the medication in conjunction with chemotherapy, extending the time it took for the cancer to worsen from 10 to 14 months.

Preliminary studies showing the benefits of combining Avastin with chemotherapy treatment were presented in June 2010, with the latest results coming from a third clinical trial to support the initial claims.

Avastin work by targeting specific blood vessels that “feed” tumors and is often prescribed for those with brain, colon, kidney and lung cancers. The FDA revoked approval for the treatment of breast cancer in November due to harmful side effects and a lack of evidence proving that it extended one’s life expectancy.

The third trial did not show any evidence that the drug helped women live longer.

According to the news source, Avastin was approved earlier this month for ovarian cancer treatment by the European Commission.